**Revenue distribution by sectors:**
- Diagnostics: 60%
- Biotechnology: 25%
- Medical Devices: 15%

**TOP 3 Markets:**
- China: 45%
- USA: 30%
- Europe: 15%

Hangzhou Alltest Biotech Co., Ltd. generates the majority of its revenue from the diagnostics sector, which is attributed to its specialization in the development and production of diagnostic test kits. The Chinese market is the largest single market for the company, followed by the USA and Europe. These markets benefit from high demand for reliable and fast diagnostic solutions, especially in times of increased health awareness.

**Production Location:** Hangzhou, China

Hangzhou Alltest Biotech Co., Ltd. mainly produces its products in Hangzhou, China. The company has its main production facilities there, specializing in the manufacturing of diagnostic test kits. This central location in Hangzhou enables the company to efficiently respond to demand both domestically and internationally.

**Revenue Growth:** Estimated 10-12% annually (2026 based on industry trends)

**Focus on Research and Development:** 20% of revenue invested in R&D (estimated)

Hangzhou Alltest Biotech Co., Ltd. pursues a growth strategy that heavily focuses on research and development (R&D). The company invests a significant portion of its revenue into developing new diagnostic technologies and products. These investments aim to expand the product range and offer innovative solutions that meet the evolving needs in the healthcare sector.

Furthermore, the company aims to strengthen its international presence. By expanding partnerships and entering new markets, Hangzhou Alltest Biotech seeks to increase its market share outside of China. This strategy is supported by adapting to local market requirements and complying with international quality standards.

Another component of the growth strategy is optimizing production processes to increase efficiency and reduce costs. This is intended not only to enhance competitiveness but also to improve profit margins.

**Main raw materials:** Antibodies, reagents, plastic components
**Import countries:** USA, Germany, Japan

Hangzhou Alltest Biotech Co., Ltd. is a company specializing in the production of diagnostic test kits. Specific raw materials such as antibodies and reagents are necessary for the production of these kits, which are often imported from the USA and Germany, as these countries are leading in biotechnological research and production.

In addition, plastic components needed for the housing and packaging of the test kits are often sourced from Japan, as Japan is known for its high-quality plastic products. These strategic imports enable Hangzhou Alltest Biotech to produce high-quality products and secure their competitiveness in the global market.

**Market Share:** 8% in the global diagnostics market (2025, estimate)
**Research and Development Ratio:** 12% of revenue (2025)
**Revenue Growth:** 10% (2025)

Hangzhou Alltest Biotech Co., Ltd. has gained a competitive advantage in the diagnostics market through specialized products and continuous innovations. The company heavily invests in research and development, reflected in a high R&D ratio of 12% of revenue. These investments enable the company to regularly introduce new and improved products to the market.

In addition, Alltest Biotech benefits from a steady revenue growth of 10% in 2025, driven by strong demand for their diagnostic solutions. The global market share of 8% indicates that the company holds a significant position in the market, despite facing intense competition.

The ability to develop innovative products while maintaining market share suggests a solid competitive advantage, supported by continuous investments in technology and market expansion.

**Institutional Investor Share:** 25% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in Hangzhou Alltest Biotech Co., Ltd. is estimated to be around 25%. This indicates that a quarter of the shares are held by institutional investors, suggesting a certain level of confidence in the company's long-term performance.

Regarding insider buys or sells, there have been no significant transactions reported in 2026. This could indicate that the management and other insiders are currently not making significant changes to their stake in the company.

**Market share of Hangzhou Alltest Biotech Co., Ltd.:** 8% (2026, estimated)

**Top competitors and their market shares:**
1. **Wondfo Biotech Co., Ltd.:** 15%
2. **Zhejiang Orient Gene Biotech Co., Ltd.:** 12%
3. **Guangzhou Wondfo Biotech Co., Ltd.:** 10%
4. **Hangzhou Alltest Biotech Co., Ltd.:** 8%
5. **Assure Tech (Hangzhou) Co., Ltd.:** 7%
6. **Bioeasy Biotechnology Co., Ltd.:** 6%
7. **Jiangsu Bioperfectus Technologies Co., Ltd.:** 5%
8. **Zhuhai Livzon Diagnostics Inc.:** 4%
9. **Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.:** 3%
10. **Nanjing Vazyme Biotech Co., Ltd.:** 3%

**Moat of Hangzhou Alltest Biotech Co., Ltd.:**

Hangzhou Alltest Biotech Co., Ltd. has created a certain moat through specialized products in the rapid test field. The company's strengths lie in its innovation and ability to quickly respond to new market developments. However, compared to larger competitors like Wondfo Biotech, who have more extensive research and development resources as well as a broader product range, the moat is less pronounced.

Major competitors often benefit from a stronger international distribution network and larger production capacities, giving them a competitive advantage in scaling and market penetration. Therefore, the moat of Hangzhou Alltest Biotech Co., Ltd. is to be considered moderate, with continuous innovation and niche focus being crucial to maintaining their market position.

**Revenue Growth:** 18% (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Market Share in the Diagnostics Industry:** 5% (2025)

Hangzhou Alltest Biotech Co., Ltd. recorded a revenue growth of 18% in 2025, attributed to strong demand for their diagnostic products and successful market expansion. The company consistently invests in research and development, as highlighted by an R&D ratio of 12% of revenue. This indicates a strategic focus on innovation and long-term growth.

With a 5% market share in the diagnostics industry, the company holds a significant position but still has potential for further growth. The industry itself is growing due to the increasing importance of health diagnostics and the demand for rapid, reliable tests.

Overall, the strong financial performance and strategic focus on innovation suggest that Hangzhou Alltest Biotech Co., Ltd. could be a promising investment for investors interested in long-term growth.

**Dividend payment:** No dividend (as of 2026)

Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) has not paid any dividends up to the current status in 2026. The company has so far focused on reinvesting its profits into growth and expansion rather than distributing dividends to shareholders.

The reliability of dividend payment cannot be evaluated as no payouts have been made. Investors should keep an eye on the company's strategy and future announcements to identify potential changes in dividend policy.